Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06572839 · ClinicalTrials.gov registry record · NA
Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
A NA study of Diabetic Foot Ulcer, sponsored by Capsicure.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 12
- Study locations
NCT06572839: Recruiting NA study of Diabetic Foot Ulcer, sponsored by Capsicure.
NCT06572839 is a NA study of Diabetic Foot Ulcer that is actively recruiting participants, run by Capsicure. The registered enrollment target is 150 participants, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (41% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06572839, a NA study of Diabetic Foot Ulcer, is actively recruiting participants, sponsored by Capsicure.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 12
- Study locations
Study Summary
This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers
Primary Outcome
To demonstrate change in healing rates of chronic wounds (diabetic foot ulcers), unresponsive to standard therapy.
Conditions Studied
Interventions
- OTHER Amnio-Maxx
Study Locations (12)
Florida
- Solutions Medical Research - Coral Gables
- Evolution Research Center - Hialeah
- Symphony Research - Jacksonville
- Quality Care Clinical Research - Miami
Texas
- Stride Clinical Research - Houston
- Ten20 Medical - Sunnyvale
Alabama
- North Alabama Research Center, LLC - Athens
California
- North Park Podiatry - San Diego
Louisiana
- Medcentris - Hammond
New Jersey
- Curalta Clinical Trials - Oradell
New York
- Suffolk Foot and Ankle - East Patchogue
Pennsylvania
- PA Foot and Ankle Associates - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2025-10-31 |
| Phase | NA |
What NCT06572839 shows while recruiting
NCT06572839 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention - of which Amnio-Maxx is the first listed.
NCT06572839 lists 12 locations in 8 states (Florida, Texas, Alabama).
Frequently Asked Questions
What is clinical trial NCT06572839 about?
NCT06572839 is a clinical study titled "Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone". This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers
What is the current status of trial NCT06572839?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-10-25. Estimated completion is 2025-10-31.
What conditions does trial NCT06572839 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer.
What interventions are being tested in trial NCT06572839?
The interventions under investigation include: Amnio-Maxx (OTHER).
Who is sponsoring clinical trial NCT06572839?
This trial is sponsored by Capsicure, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06572839 being conducted?
This trial has 12 study locations across Alabama, California, Florida, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06572839's enrollment target sits among peer trials
150 25th of 67 higher than 42 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI